Shareholders in Shenzhen Kangtai Biological Products (SZSE:300601) Are in the Red If They Invested Three Years Ago
Shareholders in Shenzhen Kangtai Biological Products (SZSE:300601) Are in the Red If They Invested Three Years Ago
While it may not be enough for some shareholders, we think it is good to see the Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) share price up 12% in a single quarter. But that is meagre solace in the face of the shocking decline over three years. The share price has sunk like a leaky ship, down 74% in that time. Arguably, the recent bounce is to be expected after such a bad drop. The thing to think about is whether the business has really turned around.
虽然这对一些股东来说可能还不够,但我们认为看到深圳市康泰生物制品有限公司。(SZSE:300601)股价单季上涨12%。但面对三年来令人震惊的下滑,这只是微不足道的安慰。该公司股价像一艘漏水的船一样下沉,在此期间下跌了74%。可以说,在经历了如此严重的下跌之后,最近的反弹是意料之中的。需要考虑的是,企业是否真的扭亏为盈了。
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
因此,让我们来看看该公司的长期业绩是否与基础业务的进展一致。
Check out our latest analysis for Shenzhen Kangtai Biological Products
查看我们对深圳康泰生物制品的最新分析
We don't think that Shenzhen Kangtai Biological Products' modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
我们认为,深圳康泰生物制品连续12个月的适度盈利目前还没有得到市场的充分关注。我们认为收入可能是更好的指引。一般来说,我们会把这样的股票和亏损的公司放在一起考虑,原因很简单,因为利润的总量太低了。要让股东有信心一家公司的利润将大幅增长,它必须增加收入。
Over three years, Shenzhen Kangtai Biological Products grew revenue at 18% per year. That's a fairly respectable growth rate. So it seems unlikely the 20% share price drop (each year) is entirely about the revenue. It could be that the losses were much larger than expected. If you buy into companies that lose money then you always risk losing money yourself. Just don't lose the lesson.
在三年的时间里,深圳康泰生物制品的收入以每年18%的速度增长。这是一个相当可观的增长率。因此,股价(每年)下跌20%似乎不太可能完全是因为收入。这可能是因为损失比预期要大得多。如果你买入赔钱的公司,那么你自己总是有赔钱的风险。只要别丢了教训就行了。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下图中看到收益和收入随时间的变化(单击图表查看确切的值)。
Shenzhen Kangtai Biological Products is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Shenzhen Kangtai Biological Products stock, you should check out this free report showing analyst consensus estimates for future profits.
深圳康泰生物制品是一只知名的股票,有大量的分析师报道,这表明对未来的增长有一定的可见性。如果你正在考虑买卖深圳康泰生物制品的股票,你应该看看这个免费显示分析师对未来利润的一致估计的报告。
A Different Perspective
不同的视角
It's good to see that Shenzhen Kangtai Biological Products has rewarded shareholders with a total shareholder return of 5.7% in the last twelve months. That's including the dividend. However, the TSR over five years, coming in at 6% per year, is even more impressive. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Shenzhen Kangtai Biological Products that you should be aware of before investing here.
很高兴看到深圳康泰生物制品在过去的12个月里以5.7%的总股东回报回报了股东。这还包括股息。然而,五年来的TSR,以每年6%的速度增长,更令人印象深刻。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。例如,我们发现深圳康泰生物制品的3个警示标志在这里投资之前你应该意识到这一点。
Of course Shenzhen Kangtai Biological Products may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然了深圳康泰生物制品可能不是最值得买入的股票。所以你可能想看看这个免费成长型股票的集合。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。